New article: HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma https://t.co/kl1YsjCYau #melanoma #oncology https://t.co/zXsftpjr3q
HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma: Background, As a recognized highly immunogenic tumor, immune checkpoint blockades (ICB) have been widely used as a systemic treatment… https://t.co/JO81J8lbwG #i
HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma: Background As a recognized highly immunogenic tumor, immune checkpoint blockades (ICB) have been widely used as a systemic treatment #immunology… https://t.co/JO
New Research: HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma: Background As a recognized highly immunogenic tumor, immune checkpoint blockades (ICB) have been widely used as a systemic treatment… https://t.co/